Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
Axios Vitals on MSN1d
PBMs made more than $7B marking up specialty generics: FTCThe three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...
The National Association of Chain Drug Stores is praising the Federal Trade Commission's (FTC) unanimous, 5-0, vote on Monday to release the second interim staff report on the FTC's study of big ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback